ECSP22005485A - Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos - Google Patents

Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos

Info

Publication number
ECSP22005485A
ECSP22005485A ECSENADI20225485A ECDI202205485A ECSP22005485A EC SP22005485 A ECSP22005485 A EC SP22005485A EC SENADI20225485 A ECSENADI20225485 A EC SENADI20225485A EC DI202205485 A ECDI202205485 A EC DI202205485A EC SP22005485 A ECSP22005485 A EC SP22005485A
Authority
EC
Ecuador
Prior art keywords
methods
macrocyclic compounds
sting agonists
compounds
macrocyclic
Prior art date
Application number
ECSENADI20225485A
Other languages
English (en)
Inventor
Deepak Walke
Vaibhav Kalhapure
Navnath Karche
Vidya Ramdas
Smita Aditya Bhoskar
Moloy Banerjee
Vinod Vyavahare
Venkata Palle
Ganesh Rajaram Jadhav
Amit Kumar Das
Nishant Ramnivasji Gupta
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ECSP22005485A publication Critical patent/ECSP22005485A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) o (II) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables, hidratos, solvatos y profármacos de los mismos y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.
ECSENADI20225485A 2019-07-22 2022-01-21 Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos ECSP22005485A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921029556 2019-07-22
IN201921051086 2019-12-10
IN202021003961 2020-01-29

Publications (1)

Publication Number Publication Date
ECSP22005485A true ECSP22005485A (es) 2022-02-25

Family

ID=72422197

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20225485A ECSP22005485A (es) 2019-07-22 2022-01-21 Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos

Country Status (17)

Country Link
US (1) US20220289763A1 (es)
EP (1) EP4004002A1 (es)
JP (1) JP2022541330A (es)
KR (1) KR20220035955A (es)
CN (1) CN114174303A (es)
AU (1) AU2020319058A1 (es)
BR (1) BR112022001125A2 (es)
CA (1) CA3147397A1 (es)
CL (1) CL2022000145A1 (es)
CO (1) CO2022001814A2 (es)
CR (1) CR20220029A (es)
EC (1) ECSP22005485A (es)
IL (1) IL289740A (es)
MX (1) MX2022000939A (es)
PE (1) PE20220937A1 (es)
WO (1) WO2021014365A1 (es)
ZA (1) ZA202201375B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543086A (ja) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
EP4134098A4 (en) 2020-04-10 2024-05-15 Ono Pharmaceutical Co CANCER THERAPY METHODS
JP2024503508A (ja) * 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
AR125608A1 (es) * 2021-03-30 2023-08-02 Jacobio Pharmaceuticals Co Ltd Novedosos compuestos útiles como agonistas de sting y sus usos

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
WO2007146981A2 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
WO2008090570A1 (en) 2007-01-25 2008-07-31 Panacea Biotec Ltd Novel antimicrobials
TW201000447A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
WO2012083053A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
CN107573275A (zh) 2012-12-28 2018-01-12 日本脏器制药株式会社 肉桂酰胺衍生物
JP6462006B2 (ja) * 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
CR20200045A (es) * 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
EP3440072B1 (en) 2016-04-07 2020-01-29 GlaxoSmithKline Intellectual Property Development Ltd Heterocyclic amides useful as protein modulators
US11352353B2 (en) 2016-05-27 2022-06-07 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound serving as FGFR4 inhibitor
EA036338B1 (ru) * 2017-02-22 2020-10-28 Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед Гетероциклические амиды, пригодные в качестве модуляторов белков
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
UA125730C2 (uk) 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини
EP3658138B1 (en) 2017-07-27 2023-04-19 Stingray Therapeutics, Inc. Substituted-3h-imidazo(4,5-c)pyridine and 1h-pyrrolo(2,3-c)pyridine series of novel ectonucleotide pyrophsphatase/phosphodiestrase-1 (enpp1) and stimulator for interferon genes (sting) modulator as cancer immunotherapeutics
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
AU2018344902B2 (en) * 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
WO2019069270A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
PE20220169A1 (es) * 2019-03-28 2022-01-28 Lupin Ltd Compuestos macrociclicos como agonistas de sting

Also Published As

Publication number Publication date
JP2022541330A (ja) 2022-09-22
IL289740A (en) 2022-03-01
CN114174303A (zh) 2022-03-11
PE20220937A1 (es) 2022-05-31
MX2022000939A (es) 2022-04-06
US20220289763A1 (en) 2022-09-15
AU2020319058A1 (en) 2022-02-17
EP4004002A1 (en) 2022-06-01
CL2022000145A1 (es) 2022-09-09
WO2021014365A1 (en) 2021-01-28
KR20220035955A (ko) 2022-03-22
CA3147397A1 (en) 2021-01-28
CR20220029A (es) 2022-03-14
BR112022001125A2 (pt) 2022-03-15
CO2022001814A2 (es) 2022-04-29
ZA202201375B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
ECSP22005485A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
NI201900029A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
ECSP21071644A (es) Compuestos macrocíclicos como agonistas de sting
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
CO2017000222A2 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CO2019005552A2 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
CO2018012485A2 (es) Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos
DOP2019000184A (es) Inhibidores selectivos de jak1
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
UY36124A (es) Derivados de carboxamida
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
CO2021007442A2 (es) Compuesto de 1,3,4-oxadiazolona y fármaco
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AR088201A1 (es) Inhibidores seleccionados de la actividad de proteina tirosina quinasa y composiciones que los contienen